Mitochondrial Peptides: The Evidence on SS-31 and MOTS-c

What this category covers

This hub covers mitochondrial peptides: compounds studied for their effects on the mitochondria, the parts of a cell that turn food into usable energy. Research on them touches oxidative stress, membrane stability, endurance, and age-related decline. The two that come up most are SS-31 (elamipretide) and MOTS-c. Use this hub to move from broad claims to specific pages and references.

As of October 2026, those two compounds sit in very different places. SS-31 is the active ingredient in Forzinity, a prescription medicine the FDA approved for Barth syndrome in September 2025. MOTS-c is unapproved everywhere, and we found no published study that has given it to people.

This page also acts as the internal map for the category. The child topics below cover narrower questions, including dosing, safety, legal exposure, and compound comparisons. Read the hub first when you need the category logic, then use the linked subtopics for the details.

The best way to use this hub is to work from the general to the specific. Start with the category mechanism, then open the subtopic that matches the exact compound or question. It helps to note each claim alongside the evidence behind it. That habit prevents a common research error: mixing strong evidence from one peptide with weak claims about another. In this category the risk is real, because the approval of SS-31 for one rare disease says nothing about MOTS-c, or about SS-31 bought as a research vial.

Core mechanisms

The core mechanisms in this category are cardiolipin binding and AMPK signaling, both tied to how mitochondria handle energy and oxidative stress. Those terms matter because peptide claims often sound similar even when the underlying pathway is different. SS-31 binds cardiolipin, a fat in the inner mitochondrial membrane; the FDA describes Forzinity as binding the inner part of the mitochondria and improving their structure and function. MOTS-c is a short peptide encoded in mitochondrial DNA. In cell and mouse studies it activates AMPK, an energy sensor that also responds to exercise. The two share a category label but act at different points, and the evidence behind them is very different.

Mechanism also sets the evidence standard. Direct receptor data can explain why a compound deserves attention, but it does not prove a human outcome. A useful review connects the pathway to measured endpoints such as walking distance, muscle strength, fatigue scores, liver enzymes, or adverse events.

Mechanisms also help separate acute effects from durable adaptation. Changes in mitochondrial function or exercise capacity, if they happen, are measured over weeks to months. In the Barth syndrome program, for example, the strength changes that supported Forzinity's approval showed up in a long open-label extension, not during the 12-week randomized phase. A careful reader looks for the timeline that fits the tissue and pathway.

Route of administration changes interpretation too. Oral and injected forms do not create identical exposure, and much of the mouse work on MOTS-c used injection into the abdominal cavity, a route people don't use. Bioavailability and degradation can both change the effective dose. When a study uses one route and a product page discusses another, treat the comparison as incomplete until the exposure difference is addressed.

Key compounds in this category

SS-31 (elamipretide)

SS-31 is the best-studied peptide in this group. On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) injection to improve muscle strength in people with Barth syndrome, a rare inherited mitochondrial disease, who weigh at least 30 kg. It was the first approved treatment for Barth syndrome. The label dose is 40 mg by subcutaneous injection once daily. Forzinity is a prescription medicine made and tested under FDA rules. Vials sold online as "SS-31" for research use are a different product and haven't been through that review.

The approval rests on thin data, which is why the site rates SS-31's evidence as moderate rather than strong. In the randomized Barth trial of 12 patients, elamipretide was not better than placebo on its primary endpoints (six-minute walk distance and fatigue). The FDA based the approval on knee-extensor strength increases seen later in the open-label extension. Other trials have missed their primary endpoints too, including the ReCLAIM-2 Phase 2 trial in dry age-related macular degeneration (176 patients), although treated patients lost less of a photoreceptor layer on imaging.

As a condition of approval, the FDA required a confirmatory randomized trial. According to the company, that trial, 4TAZPower, dosed its first patient in July 2026. It runs 72 weeks, so results are years away. In trials, the most common side effects were injection-site reactions, and the FDA also notes serious allergic reactions. Forum users who buy research vials describe about 0.5-4 mg a day, far below the label dose; no study has tested those amounts. As of October 2026, SS-31 isn't named on WADA's Prohibited List, and how anti-doping rules treat it since its approval is unverified.

MOTS-c

MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA. Its reputation for endurance and insulin sensitivity comes from mouse and cell studies. As of October 2026, we found no published study that has given native MOTS-c to people. The one registered Phase 2 trial that claims to (NCT07505745) comes from a sponsor whose registry records are disputed.

The closest thing to human data is CB4211, a modified version developed by CohBar. In a 4-week trial in 20 adults with obesity and fatty liver, liver enzymes fell more than with placebo, but liver fat dropped about the same in both groups. In 2023 CohBar said the trial formulation wasn't suitable for further development, then moved to dissolve the company that November, which ended the program.

WADA's 2026 Prohibited List names MOTS-c under S4.4.1 (AMPK activators), so it's banned at all times for tested athletes. Our page on peptides and anti-doping rules covers what a positive test costs.

Practical considerations

Human data are limited for everything here except SS-31 in Barth syndrome, so a cautious reading treats endurance and recovery claims as unproven. The useful process is a checklist: what pathway is targeted, what outcome was measured, and whether a dose comes from a human study, an animal model, or informal user practice. Those sources should not be weighted the same way.

Dose ranges on this site are research context, not personal instructions. SS-31 shows why the source matters: the approved label dose is 40 mg a day for Barth syndrome, while forum users describe a few milligrams a day with no trial behind it. A number only means something when it is paired with the compound and the population it was tested in.

Timing claims deserve the same scrutiny. Some users take MOTS-c before training because mouse studies link it to exercise capacity, but no study has tested timing in people.

Product quality changes the practical risk more than many readers expect. A clean protocol on paper can fail if the vial is mislabeled, underfilled, contaminated, or degraded by heat. Research-use-only vendors may publish COAs, but a COA is only useful when it identifies the exact lot, the test method, the purity result, and the date. The safer comparison is not just peptide A against peptide B, but source A against source B with evidence attached.

Monitoring questions differ by compound. For SS-31, the trial data point to injection-site reactions and allergic reactions as the main known risks. For MOTS-c there are no human safety data to go on; itchy injection-site welts are the most common complaint in user reports. Legal and competition status should be checked before any purchase, not after a problem appears.

Subtopics in this category:

• Comparative Analysis Mitochondrial Peptides
• Comparative Analysis Peptides vs Anabolics
• Comparative Efficacy Mitochondrial vs Steroids
• Comparative Efficacy Peptides vs Steroids
• Comparative Efficacy Peptides vs Anabolics
• Legal Ethical Considerations Athletes
• Legal Landscape Sports
• Long Term Effects Bodybuilding
• Long Term Health Implications
• Peptide Cycling Protocols
• Peptide Cycling Strategies Fat Loss
• Peptide Synthesis Techniques
• Regulatory Changes Sports
• Regulatory Landscape Sports
• Safety Regulation Sports
• Synergistic Effects Supplements
• Mitochondrial Health Aging Muscle
• MOTS-c Endurance
• SS-31 Recovery
• Endurance Applications
• MOTS-c
• SS-31

Risks and unknowns

Energy benefits are easy to over-attribute. Long-term safety data are thin: the longest human exposure to SS-31 is a handful of Barth patients treated for more than three years in the extension study, and native MOTS-c has none. The most common mistake is treating "research peptide" as a safety label. It is a sales and labeling phrase. It does not confirm sterility, identity, dose accuracy, legal status, or suitability for human use.

Unknowns matter most when people stack compounds. If 3 peptides start in the same week, a side effect cannot be traced cleanly. If a dose increases while training load and diet also change, the outcome cannot be attributed cleanly either. Better research practice changes one variable at a time and keeps records.

Long-term data is uneven. Some metabolic peptides have large human trials, while most mitochondrial compounds rely on small studies, animal data, or mechanistic rationale. The level of caution should match the quality of evidence.

Contraindications often sit outside the peptide discussion itself. A reader with cancer history, diabetes medication, autoimmune disease, active infection, pregnancy, or a scheduled surgery may face a different risk profile than a healthy athlete. The public literature rarely covers every scenario. That is why this site treats medical supervision and conservative interpretation as part of the research framework rather than optional extras.

Another mistake is confusing legal availability with evidence quality. A compound can be easy to buy and still have limited human data. A prescription drug can have strong evidence and still be inappropriate without a clinician. A banned sport substance can be legal in some medical contexts and prohibited in competition. Keep those questions separate: legality, evidence, product quality, and individual risk are different filters.

How this category connects to others

This category overlaps with several others. Our overview of what the clinical peptide data says explains how to weigh human trials against animal work, and the guide to reading reported peptide doses covers why label doses carry more weight than user reports. For metabolic claims, see the fat-loss peptide hub, and for a side-by-side with steroids and SARMs, see that comparison. The legal status hub explains what a research-use-only label does and doesn't mean.

Non-peptide variables matter as much here as anywhere. Sleep and training load both affect endurance and recovery, the outcomes these compounds are bought for. When those shift at the same time as a new peptide, a change in how someone feels becomes a story rather than useful research.

A sensible reading order is the subtopic that matches your question, then the compound profile if one exists, and the product page only after the mechanism and safety questions are clear. That order keeps commercial pages in context and helps prevent a purchase decision from driving the research conclusion.